SAYREVILLE, N.J. and MARIETTA, Ga., February 4, 2016 /PRNewswire/ — Vertical / Trigen Holdings, LLC (“Vertical / Trigen”) and Osmotica Holdings Corp Limited (“Osmotica”) today announced the successful completion of their previously announced combination, creating a world-class, fully-integrated specialty pharmaceutical and generics company. The combined company, which will retain the Osmotica name, is jointly owned by the owners of Vertical / Trigen and Osmotica, including Avista Capital Partners.
The company will continue to offer Vertical / Trigen’s full portfolio of branded and generic products, as well as Osmotica’s successful extended-release formulations upon achieving the required regulatory approval.
Brian Markison, Healthcare Industry Executive at Avista Capital Partners and formerly Executive Chairman of Vertical / Trigen, has been appointed chief executive officer of the combined company. “We are pleased to have completed this strategic combination, which brings together two highly complementary businesses with demonstrated track records of developing commercially successful pharmaceutical products,” said Mr. Markison. “I look forward to working with the combined team to ensure that the new Osmotica builds on the strengths of both companies to deliver greater value for physicians, patients and the healthcare system overall.”
About Vertical / Trigen
Vertical Pharmaceuticals, LLC was founded in 2003 with a mission to develop, market, and acquire products offering therapeutic benefits for patients and healthcare providers. Vertical Pharmaceuticals supplies niche over the counter and prescription pharmaceutical preparations, specializing in women’s health and pain management. Vertical’s medications are marketed by its dedicated sales force throughout the United States.
Trigen Laboratories, LLC is a generic pharmaceutical company offering unique products across an increasing array of categories. Trigen seeks to bring value-driven generic products to its customers, working vigorously with its partners to identify and develop products which face an assortment of challenges. Additionally, Trigen identifies unique marketing opportunities and is steadfast in its pursuit to deliver products to best serve these markets.
Osmotica Holdings Corp Limited is a global specialty pharmaceutical company with a proven history of developing commercially successful pharmaceutical products. The Company uses its proprietary osmotic technology platform and with strategic partners develops and commercializes high quality pharmaceutical products. In addition to the products currently on the market, the Company’s pipeline includes numerous ANDA programs and several innovative neurology-based NDA programs.
Osmotica Holdings Corp Limited and its related companies form an international group of companies with principal operations located in the United States, Argentina and Hungary.
For more information on the Company, please visit Osmotica’s website at www.osmotica.com.
About Avista Capital Partners
Avista Capital Partners is a leading private equity firm with approximately $6 billion under management and offices in New York, Houston and London. Founded in 2005, Avista makes controlling or influential minority investments in growth-oriented healthcare, industrial and communications businesses. Through its team of seasoned investment professionals and industry experts, Avista seeks to partner with exceptional management teams to invest in and add value to well-positioned businesses. (www.avistacap.com)
James David and Kathleen Pierre
James.David@kekst.com / Kathleen.Pierre@kekst.com